Background and importance Malnutrition is one of the strongest predictors of mortality and morbidity in haemodialysis patients. Albumin levels are used as an indicator of its severity and concentrations under 3.8 g/dL indicate severe malnutrition. As first-line treatment, guidelines recommend nutritional counselling and oral nutrition supplements. Furthermore, parenteral nutrition during regular haemodialysis sessions, known as intradialytic parenteral nutrition (IDPN), is an option for patients who cannot tolerate oral or enteral routes for nutrition supplements.

Aim and objectives The aim of this study was to evaluate the effects of IDPN on albumin concentrations in malnourished haemodialysis patients.

Material and methods Observational retrospective study carried out with patients who had been in treatment with IDPN in the last 5 years, from April 2016 to April 2021. Age, sex, height, weight, body mass index, IDPN start and end dates, and albumin levels were collected to create database. Statistical evaluation was done using Rcommander software.

Results In this 5-year period, the total number of patients was 7 (N=7). Initial albumin levels were under 3.8 g/dL in 100% of the patients and the mean was 2.7 ± 0.58 g/dL. Mean duration of IDPN was 36 (3–150) days. Albumin concentrations increased in all patients and the mean increase was 0.80 ± 0.32 g/dL. In addition, 42.9% of the patients (n=3) attained albumin levels higher than 3.8 g/dL. Mean ± 0.32 g/dL. In addition, 42.9% of the patients (n=3) attained albumin levels higher than 3.8 g/dL.

Conclusion and relevance IDPN has shown an improvement in albumin concentrations among haemodialysis patients; however, further investigations are required to establish a relation with mortality and morbidity.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of interest No conflict of interest
2021). Persistence after the first year of treatment was also assessed.

Sociodemographic and clinical factors (age, age of diagnosis, DM phenotype, baseline Expanded Disability Status Scale (EDSS), treatment with disease-modifying therapies (DMTs) and anti-spasticity agents and walking support request) were collected from medical record. Persistence and adherence (measured as medication possession ratio (MPR)) data were collected from drug dispensation records (FarmaTools).

For the analysis of persistence a survival analysis with the Kaplan-Meier estimator was performed. Influence of covariates was evaluated according to a Cox regression model. All statistical analyses were performed using SPSS V24.0. Significance level was 0.05.

Results Fifty-one patients were included. Mean±SD age of MS diagnosis was 37.3±12.6 years. 62.7% female. At the start of the treatment, mean±SD age was 49.7±10.0 years. Phenotypes were relapsing-remitting (49%), secondary progressive (41.2%) and primary progressive (9.8%). 68.6% were on treatment with DMTs and 60.8% with anti-spasticity agents. 58.8% required support to walk. Baseline EDSS was 5±1.3. Median adherence in first year was 98.5±4.5%.

Median persistence duration was 1.756 days (95% CI 1.405 to 2.107). Median time to suspension was 84 days (IQR 28–114). Medication suspension rate in first year was 31.4% and overall medication suspension rate was 13/100 patients/year (95% IC 8.1 to 17.9). Discontinuation reasons were lack of efficacy (57.9%), adverse effects (23.1%) or both (14.3%). Cox model showed only influence of age of DM diagnosis HR=1.05 (95% CI 1.01 to 1.07; p=0.007).

Conclusion and relevance A high percentage of patients abandon treatment with fampridine, mainly due to lack of efficacy. Most discontinuations occur in the first year of treatment.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Conflict of interest No conflict of interest

4CPS-129 ADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY
R Castillejos*, A Aguado Paredes, A Martinez Suarez, L Mofráno Domínguez, L Martín Casado, M Romero González. Clinical Pharmacist, Hospital Universitario Vigo Macarena, Seville, Spain
10.1136/ehjpharm-2022-eahp.395

Background and importance Antibiotics constitute one of the main groups of drugs prescribed for hospitalised patients. Many of them present renal elimination, which is why in cases of impaired renal function is necessary to adjust the dose.

Aim and objectives To evaluate physician acceptance of pharmacist recommendation (PR) in patients with renal insufficiency.

Material and methods Prospective interventional study from June to September 2021. We included all patients who started antibiotic treatment with a glomerular filtration rate less than 50 mL/min. Data were collected from the electronic medical record (DIRAYA) and the prescription program (PRISMA). Dose adjustment recommendations were made based on the antibiotic datasheets and the Sanford Guide to Antimicrobial Therapy.

Data collected: sex, age, clinical service, prescribed antibiotic.

Recommendations were reported in the clinical course of the patient. In the case of severe kidney failure, the prescribing doctor was notified directly. Descriptive statistics were used to analyse the results.

Results 40 patients (60% men) were analysed, with a median age of 78 (range 48–92) years. 42 dose adjustment recommendations were made. The antibiotics evaluated were: piperacillin/tazobactam (22), meropenem (9), amoxicillin/clavulanic (7), vancomycin (2), ertapenem (1) and cefazidime (1). Clinical services involved were: Internal Medicine (19), Urology (10), Cardiology (3), Digestive (3) Oncology (3), Traumatology (3) and Pneumology (1).

The rate of acceptance of PR was 79.5%; 67.7% dose reduction and 33.3% dose increase. 7.1% of the PR cannot be valued due to a change in treatment.

Conclusion and relevance The hospital pharmacist plays an important role in the correct, effective and safe use of antibiotic therapy, especially, as occurs in our study, in elderly patients. Thanks to the pharmacist-doctor communication, the number of recommendations made decreased over time in certain clinical areas due to the correct dose adjustments by the prescribing doctors.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Sanford Guide to Antimicrobial Therapy. Conflict of interest No conflict of interest

4CPS-130 ANALYSIS OF THE DIFFERENT CARDIOVERSION STRATEGIES IN THE EMERGENCY DEPARTMENT IN A SECONDARY HOSPITAL
1R Rodriguez Mauriz*, 1L Bonnàs Trías, 2N García Farre, 1N Almendros-Abad, 1N Rudi Sola. 1Hospital General de Granollers, Pharmacy Department, Granollers, Spain; 2Hospital General de Granollers, Emergency Department, Granollers, Spain
10.1136/ehjpharm-2022-eahp.396

Background and importance Acute atrial fibrillation (AF) is the most common arrhythmia managed in the emergency department (ED). Conversion to normal sinus rhythm can be performed by electrical (ECV) or pharmacological cardioversion. ECV is more effective and it is the method of choice for haemodynamically unstable patients or new onset AF; however, pharmacological cardioversion does not require anaesthesia and it is easier to attempt.

The choice to pursue rhythm control is an individualised one according to the clinical profile of the patient and the therapeutic options available.

Aim and objectives To analyse the strategies to restore sinus rhythm for ED patients with acute AF and the results obtained.

To analyse the time from AF onset to restoration of sinus rhythm.

Material and methods Observational, retrospective, multidisciplinary study. Inclusion criteria: patients >18 years treated at the ED (June 2020–February 2021) with diagnosis of AF in which it was decided to restore sinus rhythm.

Variables demographic, comorbidities (chronic renal failure, diabetes, obesity), haemodynamic stability (yes/no), structural heart disease, type of cardioversion (ECV or pharmacological), drug used in pharmacological cardioversion, conversion to normal sinus rhythm (yes/no), time to restoration of rhythm, rescue cardioversion if failure.